Trastuzumab

USDailyMed:Trastuzumab AU:D L01FD01(WHO) AU:S4(Prescription only)CA:℞-only/ Schedule DUS:℞-onlyEU:Rx-only 180288-69-1Y 46507516 DB00072Y none P188ANX8CK D03257Y ChEMBL1201585N Trastuzumab, sold under the brand nameHerceptinamong others, is amonoclonal antibodyused to treatbreast cancerandstomach cancer.It is specifically used for cancer that isHER2 receptor positive.It may be used by itself or together with otherchemotherapy medication.Trastuzumab is given byslow injection into a veinandinjection just under the skin. Common side effects include fever, infection, cough, headache, trouble sleeping, and rash.Other severe side effects includeheart failure,allergic reactions, andlung disease.Use duringpregnancymay harm the baby.Trastuzumab works by binding to theHER2 receptorand slowing down cell replication. Trastuzumab was approved for medical use in the United States in September 1998, and in the European Union in August 2000.It is on theWorld Health Organization's List of Essential Medicines.